Phaseline

Companies › Grifols Biologicals

Grifols Biologicals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Alphanate SD/HT
Factor VIII/von Willebrand Factor (vWF) concentrate
F8, VWFPhase 4Von Willebrand Disease–
Gamunex-C, 10% Injectable Solution
Intravenous immunoglobulin (IVIG)
–Phase 3Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00555555Alphanate SD/HTPhase 4Von Willebrand DiseaseHematologyFeb 2012
NCT07582432Gamunex-C, 10% Injectable SolutionPhase 3Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaOncologyAug 2028

Targets

F8 (1) VWF (1)

Companies with the same targets

Pfizer Roche Swedish Orphan Biovitrum Sinocelltech Octapharma ASC Therapeutics Bioverativ, a Sanofi company Biocad Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.